Pegylated Interferon Lambda

BIOLOGICAL3 trials

Sponsors

Bristol-Myers Squibb, Raymond Chung

Conditions

COVIDCOVID-19Hepatitis CHepatitis C Virus (HCV)

Phase 2

Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin

CompletedNCT01795911

Bristol-Myers SquibbHepatitis C

Start: 2013-03-31End: 2014-09-30Updated: 2015-10-09

Pegylated Interferon Lambda Treatment for COVID-19

TerminatedNCT04343976

Raymond ChungCOVID, COVID-19

Start: 2020-06-22End: 2021-07-30Updated: 2022-07-21

Phase 3

Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C

WithdrawnNCT01447394

Bristol-Myers SquibbHepatitis C Virus (HCV)

Start: 2012-03-31End: 2014-08-31Updated: 2012-02-03

Related Papers

Peginterferon lambda for the treatment of hospitalized patients with mild COVID-19: A pilot phase 2 randomized placebo-controlled trial

Frontiers in Medicine2023-02-242 citations

Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial.

2021-03-30114 citations